BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

China’s WuXi Biologics Secures SBTi Approval for Net-Zero Targets, Reinforcing Global Green CRDMO Leadership

Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Gre...

August 29, 2025 | News

China’s LakeShore Biopharma Receives Revised Take-Private Proposal from Oceanpine Capital-Led Consortium

LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developin...

August 29, 2025 | News

China’s D3 Bio Secures FDA Breakthrough and Orphan Drug Designations for KRAS G12C Inhibitor D3S-001

Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cel...

August 29, 2025 | News

Cold Chain Technologies accelerates APAC expansion with new hubs, distributors, and manufacturing site

Cold Chain Technologies (CCT), has reinforced its commitment to expanding its Asia Pacific (APAC) presence with a series of investments and partnerships. ...

August 28, 2025 | News

Neusoft Medical Secures China’s First Approval For Photon-Counting CT With NeuViz P10

Neusoft Medical Systems announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Product...

August 28, 2025 | News

Basecare Medical Secures NMPA Approval For VitBase Culture Medium Marking Breakthrough In China’s Assisted Reproductive Field

Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has offic...

August 27, 2025 | Regulatory

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

China’s Bio-Thera and Europe’s STADA Expand Biosimilars Alliance to Include Tocilizumab

Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the...

August 25, 2025 | News

BioDlink Secures Indonesian Approval for Bevacizumab, Accelerating ASEAN and Global Expansion

BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Con...

August 22, 2025 | News

Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025

The first eight months of 2025 have been transformative for biosupplier technologies worldwide. From innovative lab reagents and biomaterials to ad...

August 22, 2025 | Analysis

RemeGen and Santen Form Strategic Alliance on RC28-E for Asia and Greater China

RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...

August 20, 2025 | News

WuXi Biologics Posts Robust H1 2025 Results with Margin Expansion and Record Project Wins

Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded b...

August 20, 2025 | Company results

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Stay Connected